Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics


Avenue Therapeutics, Inc. (ATXI): $2.41

-0.31 (-11.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATXI Stock Price Chart Interactive Chart >

Price chart for ATXI

ATXI Price/Volume Stats

Current price $2.41 52-week high $12.34
Prev. close $2.72 52-week low $2.22
Day low $2.33 Volume 884,700
Day high $2.77 Avg. volume 310,966
50-day MA $4.49 Dividend yield N/A
200-day MA $5.77 Market Cap 40.36M

Avenue Therapeutics, Inc. (ATXI) Company Bio


Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.


ATXI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATXI Latest Social Stream


Loading social stream, please wait...

View Full ATXI Social Stream

Latest ATXI News From Around the Web

Below are the latest news stories about Avenue Therapeutics Inc that investors may wish to consider to help them evaluate ATXI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investors!

William White on InvestorPlace | May 19, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week right with a collection of the biggest pre-market stock movers for Monday that investors need to know about.

William White on InvestorPlace | May 3, 2021

BioRad (BIO) to Report Q1 Earnings: What's in the Cards?

Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.

Yahoo | April 26, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. (“Avenue” or the “Company”) (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Avenue and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 13, 2021, Avenue issued a press release “announc[ing] that the U.S. Food and Drug Administration (‘FDA’) was still reviewing its New Drug Application (‘NDA’) for IV tramadol and had not provided a decision regarding the NDA.” The Company’s resubmitted NDA for the treatment, which ...

Yahoo | April 24, 2021

What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Yahoo | April 23, 2021

Read More 'ATXI' Stories Here

ATXI Price Returns

1-mo -45.10%
3-mo -62.52%
6-mo -63.21%
1-year -77.83%
3-year -37.40%
5-year N/A
YTD -59.50%
2020 -38.02%
2019 77.78%
2018 49.17%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6957 seconds.